logo
    Intratumoral G100 Induces Systemic Immunity and Abscopal Tumor Regression in Patients with Follicular Lymphoma: Results of a Phase 1/ 2 Study Examining G100 Alone and in Combination with Pembrolizumab
    Blood (2017)
    Christopher R. FlowersCarlos PanizoIris IsufiAlex F. HerreraCraig OkadaElizabeth H. CullBéla KisJorge ChavesNancy L. BartlettWeiyun Z. AiLuís de la Cruz-MerinoLocke J. BryanRoch HouotKim LintonJavier BrionesIan ChauGottfried R. von KeudellHailing LuFrank J. HsuAhmad Halwani
    7
    Citation
    0
    Reference
    20
    Related Paper
    Citation Trend
    Keywords:
    Follicular lymphoma
    Abscopal effect
    Topics:
    Lymphoma Diagnosis and Treatment
    Cancer Immunotherapy and Biomarkers
    Immune Cell Function and Interaction
    Results of a Phase 2, Open-Label Study of Idarubicin (I), Cytarabine (A) and Nivolumab (Nivo) in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)
    Blood (2018)
    Rita AssiHagop M. KantarjianNaval DaverGuillermo Garcia‐ManeroChristopher B. Benton
    Idarubicin
    Regimen
    Chemotherapy regimen
    Citations (24)
    Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Blood (2018)
    John RadfordBrad S. KahlMehdi HamadaniCarmelo Carlo‐StellaPaolo F. Caimi
    Antibody-drug conjugate
    Tolerability
    Follicular lymphoma
    Interim analysis
    Pharmacodynamics
    Citations (9)
    Phase II Trial of Ofatumumab (OFA) in Previously Untreated Follicular Non-Hodgkin Lymphoma (NHL): CALGB 50901 (Alliance)
    Blood (2015)
    Cara A. RosenbaumBrandelyn N. PitcherNancy L. BartlettSonali M. SmithJane Jijun Liu
    Clinical endpoint
    Follicular lymphoma
    Ofatumumab
    Progression-free survival
    Citations (5)
    LYMRIT 37-01: A Phase I/II Study of 177lu-Lilotomab Satetraxetan (Betalutin®) Antibody-Radionuclide-Conjugate (ARC) for the Treatment of Relapsed Non-Hodgkin's Lymphoma (NHL) — Analysis with 6-Month Follow-up
    Blood (2018)
    Arne KolstadUlf MadsbuMatthew BeasleyMichael BayneTim Illidge
    Refractory (planetary science)
    Citations (9)
    Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma
    Blood (2019)
    Chelsea C. PinnixJillian R. GuntherBouthaina S. DabajaSherry AdkinsMisha Hawkins
    Refractory (planetary science)
    Cell therapy
    Salvage therapy
    Citations (7)
    Nivolumab (Nivo) with Azacytidine (AZA) in Patients (pts) with Relapsed Acute Myeloid Leukemia (AML) or Frontline Elderly AML
    Blood (2017)
    Naval DaverGuillermo Garcia‐ManeroSreyashi BasuJorgé E. CortesFarhad Ravandi
    Citations (11)
    Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma
    Blood (2020)
    Alex F. HerreraLu ChenYago NietoLeona HolmbergPatrick B. Johnston
    Brentuximab vedotin
    Salvage therapy
    Refractory (planetary science)
    Citations (20)
    Phase 2 Study of Combination of Cytarabine, Idarubicin, and Nivolumab for Initial Therapy of Patients with Newly Diagnosed Acute Myeloid Leukemia
    Blood (2017)
    Farhad RavandiNaval DaverGuillermo Garcia‐ManeroChristopher B. BentonPhilip A. Thompson
    Idarubicin
    Regimen
    Citations (16)
    Pembrolizumab in Combination with Standard RCHOP Therapy for Previously Untreated Diffuse Large B-Cell Lymphoma
    Blood (2018)
    Stephen D. SmithRyan C. LynchBrian G. TillAndrew J. CowanQian Wu
    Follicular lymphoma
    Citations (3)
    Phase I/II Study of Pembrolizumab for Progressive Diffuse Large B Cell Lymphoma after Anti-CD19 Directed Chimeric Antigen Receptor Modified T Cell Therapy
    Blood (2017)
    Elise A. ChongJ. Joseph MelenhorstJakub SvobodaSunita D. NastaDaniel J. Landsburg
    Clinical endpoint
    Citations (22)